At a glance
ClinicalIndex Comparison Record- ✓Structural heart disease (ischemic or non-ischemic cardiomyopathy)
- ✓Implanted ICD and/or CRT-D device
- ✓Prior ≥1 failed catheter ablation for sustained monomorphic VT
- ✓Or catheter ablation not feasible
- ✕Only premature ventricular contractions (no sustained VT)
- ✕Acute myocardial infarction
- ✕Primary electrical disease (channelopathy)
- ✕Reversible/treatable VT cause (drug-induced, intoxication)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dose Escalation for Stereotactic Cardiac Radiation Therapy of Recurrent Ventricular Tachyarrhythmia - a Multi Center, Phase II Clinical Trial
In Brief
A Phase 1 clinical trial evaluating Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT) for Ventricular Tachycardia. Currently recruiting, targeting 15 participants across 2 sites in 2 countries.
Detailed Summary
The objective of this study is to demonstrate that higher radiation doses are necessary to induce transmural scar formation which is currently assumed to be the underlying mechanism of successful long-term efficacy of VT treatment and therefore dose-escalation will lead to a significantly reduced long-term VT recurrence rate compared to the currently applied single dose of 25 Gy.
Study Details
Timeline
Interventions
Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT) refractory to conventional antiarrhythmic and catheter ablation-based therapy. First patients will be treated with a dose from 25 Gy prescribed to the 65-90% target volume encompassing isodose escalating to a maximum of 32.5 Gy prescribed to the 65-90% isodose.